Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37736   clinical trials with a EudraCT protocol, of which   6184   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2012-003308-10
    Sponsor's Protocol Code Number:ARQ197-A-U303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2012-12-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2012-003308-10
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    A Phase 3, Randomized, Double-Blind Studio di Fase 3, randomizzato, in doppio cieco su tivantinib (ARQ 197) in pazienti affetti da carcinoma epatocellulare(HCC) non operabile con MET elevato diagnostico trattati con una precedente terapia sistemica
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to determine whether tivantinib is safe and effective in the treatment of liver cancer
    Studio clinico per determinare la sicurezza e l'efficacia di tivantinib nel trattamento del tumore epatico.
    A.3.2Name or abbreviated title of the trial where available
    ARQ 197-A-U303
    ARQ 197-A-U303
    A.4.1Sponsor's protocol code numberARQ197-A-U303
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDAIICHI SANKIO DEVELOPMENT LIMITED
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportArQule, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationDAIICHI SANKIO DEVELOPMENT LIMITED
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressChiltern Place, Chalfont Park
    B.5.3.2Town/ cityGerrards Cross, Buckinghamshire
    B.5.3.3Post codeSL9 0BG
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number0044 1753482800
    B.5.5Fax number0044 1753899107
    B.5.6E-mailinfo@dsd-eu.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTivantinib
    D.3.2Product code ARQ 197
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTivantinib
    D.3.9.2Current sponsor codeARQ 197
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number120
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC)
    Carcinoma epatocellulare (HCC) non operabile con MET elevato diagnostico
    E.1.1.1Medical condition in easily understood language
    Advanced Liver Cancer
    Tumore epatico avanzato
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10019828
    E.1.2Term Hepatocellular carcinoma non-resectable
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate overall survival (OS) among all subjects in the intent-to-treat (ITT) population compared to placebo.
    Valutare la sopravvivenza globale (OS) tra tutti i pazienti nella popolazione intent-to-treat (ITT) rispetto al placebo.
    E.2.2Secondary objectives of the trial
    Evaluate progression free survival (PFS) by central, independent radiology review among all subjects in the intent-to-treat (ITT) population compared to placebo. Evaluate safety of tivantinib in the treated HCC subjects.
    Valutare la sopravvivenza libera da progressione (PFS) mediante revisione radiologica centrale, indipendente tra tutti i pazienti nella popolazione intent-to-treat (ITT) rispetto al placebo. Valutare la sicurezza di tivantinib nei pazienti affetti da HCC trattati.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PHARMACOECONOMIC:
    Vers:1.0
    Date:2012/09/21
    Title:A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Objectives:Please refer to the protocol

    PHARMACOGENOMIC:
    Vers:1.0
    Date:2012/09/21
    Title:A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Objectives:Please refer to the protocol

    PHARMACOKINETIC/PHARMACODYNAMIC:
    Vers:1.0
    Date:2012/09/21
    Title:A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Objectives:Please refer to the Clinical Study Protocol

    LIFE QUALITY:
    Vers:1.0
    Date:2012/09/21
    Title:A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Objectives:Please refer to the protocol

    FARMACOECONOMIA:
    Vers:1.0
    Data:2012/09/21
    Titolo:Studio di Fase 3, randomizzato, in doppio cieco su tivantinib (ARQ 197) in pazienti affetti da carcinoma epatocellulare(HCC) non operabile con MET elevato diagnostico trattati con una precedente terapia sistemica.
    Obiettivi:Fare riferimento al protocollo

    FARMACOGENOMICA:
    Vers:1.0
    Data:2012/09/21
    Titolo:Studio di Fase 3, randomizzato, in doppio cieco su tivantinib (ARQ 197) in pazienti affetti da carcinoma epatocellulare(HCC) non operabile con MET elevato diagnostico trattati con una precedente terapia sistemica.
    Obiettivi:Fare riferimento al protocollo

    FARMACOCINETICA/FARMACODINAMICA:
    Vers:1.0
    Data:2012/09/21
    Titolo:Studio di Fase 3, randomizzato, in doppio cieco su tivantinib (ARQ 197) in pazienti affetti da carcinoma epatocellulare(HCC) non operabile con MET elevato diagnostico trattati con una precedente terapia sistemica.
    Obiettivi:Fare riferimento al Protocollo Clinico di studio

    QUALITA DELLA VITA:
    Vers:1.0
    Data:2012/09/21
    Titolo:Studio di Fase 3, randomizzato, in doppio cieco su tivantinib (ARQ 197) in pazienti affetti da carcinoma epatocellulare(HCC) non operabile con MET elevato diagnostico trattati con una precedente terapia sistemica.
    Obiettivi:Fare riferimento al protocollo

    E.3Principal inclusion criteria
    1. Written informed consent granted prior to initiation of any study-specific screening procedures 2. 18 years of age or older 3. Histologically confirmed HCC that is inoperable (where surgery is not indicated due to disease extension, co-morbidities, or other technical reasons) and not eligible for local therapy 4. MET Diagnostic-High tissue reported by the central authorized laboratory using archival or recent biopsy tumor samples (see lab manual and Section 6.1 of protocol for tissue preparation details). 5. Received at least 4 weeks of one prior sorafenib containing systemic therapy and then experienced documented radiographic disease progression; or inability to tolerate prior therapy received for at least a minimum period of time. For the purpose of this study, intolerance to sorafenib is determined as follows: • The subject must have tried to take sorafenib for a period of at least 28 days (even intermittently) • The subject must have tried to dose reduce sorafenib at ≤50% of the full dose for a period of at least 14 days (even intermittently) and still have a documented Grade ≥2 toxicity • A period of even less than 14 days on sorafenib is acceptable in case of: i. Uncontrolled Grade 3 - 4 arterial hypertension ii. Pancreatitis, cardiac event, encephalopathy related to sorafenib iii. ≥ Grade 2 Hand-foot syndrome triggered even at 50% of the sorafenib dose 6. Discontinued prior systemic treatment or any investigational drug for at least 2 weeks (14 days) or for at least 3 weeks for IV anti-cancer drugs, prior to the study randomization 7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1 (Appendix 17.2) 8. Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥ 4 weeks prior to randomization and are allowed. 9. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumor lesions previously treated with local therapy should demonstrate clear dimensional increase by radiographic assessment in order to be selected as target lesion(s) at baseline. Baseline radiographic assessment needs to be done within 21 days prior to randomization. 10. Adequate bone marrow, liver, and renal functions at Screening Visit, defined as: platelet count ≥ 60 × 109/L; hemoglobin ≥ 9.0 g/dL; absolute neutrophil count (ANC) ≥ 1.5 × 109/L; total bilirubin ≤ 2 mg/dL; Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 5 × upper limit of normal (ULN); serum creatinine ≤ 1.5 × ULN; albumin ≥ 2.8 g/dL; international normalized ratio (INR) 0.8 to ULN or ≤ 3 for subjects receiving anticoagulant such as coumadin or heparin. Subjects who are therapeutically anticoagulated are allowed to participate provided that prior to anticoagulant therapy no evidence of underlying defect in coagulation exists 11. Women of childbearing potential must have a negative serum pregnancy test performed within 14 days prior to the randomization (where demanded by local regulations, test may be required within 72 hours prior to randomization) 12. Male and female subjects of child-bearing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after last study drug dose received 13. Life expectancy of at least 12 weeks
    1.Consenso informato scritto ottenuto prima di iniziare qualsiasi procedura di screening specifica dello studio. 2.Età non inferiore a 18 anni 3.HCC confermato istologicamente e non operabile (casi in cui l’intervento chirurgico non è indicato per l’estensione della malattia, le comorbidità o altre ragioni tecniche) e non idoneo alla terapia locale. 4.Tessuto con MET elevato diagnostico riportato dal laboratorio centrale autorizzato, utilizzando campioni bioptici recenti o archiviati del tumore (fare riferimento al manuale del laboratorio e alla sezione 6.1 del protocollo per i dettagli sulla preparazione dei tessuti). 5.Trattamento pregresso di almeno 4 settimane con una terapia sistemica a base di sorafenib, e successiva progressione della malattia documentata radiologicamente; o incapacità di tollerare la precedente terapia ricevuta almeno per un periodo minimo di tempo. Per lo scopo dello studio, l’intolleranza al sorafenib viene determinata come segue: •Il paziente deve aver cercato di assumere sorafenib per un periodo di almeno 28 giorni (anche se non continuativamente); •Il paziente deve aver cercato di ridurre la dose di sorafenib a ≤ 50% della dose totale per un periodo di almeno 14 giorni (anche se non continuativamente) e presentare ancora una tossicità di Grado ≥ 2 documentata; •Un periodo di terapia con sorafenib inferiore a 14 giorni è accettabile in caso di: i. ipertensione arteriosa di Grado 3-4 non controllata; ii. pancreatite, evento cardiaco, encefalopatia correlata al sorafenib; iii. Sindrome mano-piede di Grado ≥ 2 scatenata anche dal 50% della dose di sorafenib. 6. Trattamento sistemico pregresso o qualsiasi farmaco sperimentale interrotto da almeno 2 settimane (14 giorni) o da almeno 3 settimane in caso di farmaco antineoplastico per via endovenosa, prima della randomizzazione per lo studio. 7. Performance Status (PS) ECOG (Eastern Cooperative Oncology Group) ≤ 1 (Appendice 17.2). 8. Terapia locale o loco-regionale (cioè, intervento chirurgico, radioterapia, embolizzazione dell’arteria epatica, chemioembolizzazione, ablazione con radiofrequenza, iniezione percutanea di etanolo o crioablazione) deve essere stata completata ≥ 4 settimane prima della randomizzazione. 9. Malattia misurabile come definito dai criteri RECIST (Response Evaluation Criteria in Solid Tumors), versione 1.1. Le lesioni tumorali trattate in precedenza con terapia locale devono mostrare un’evidente aumento di dimensione mediante valutazione radiologica per essere selezionate come lesioni target al momento iniziale. La valutazione radiologica basale deve essere eseguita nei 21 giorni precedenti alla randomizzazione. 10. Funzionalità midollare ossea, epatica e renale adeguate alla visita di screening, definite come: conta delle piastrine ≥ 60 × 109/l; emoglobina ≥ 9,0 g/dl; conta assoluta dei neutrofili (ANC) ≥ 1,5 × 109/l; bilirubina totale ≤ 2 mg/dl; alanina transaminasi (ALT) e aspartato aminotransferasi (AST) ≤ 5 × il limite superiore di normalità (ULN); creatinina sierica ≤ 1,5 × ULN; albumina ≥ 2,8 g/dl; rapporto internazionale normalizzato (INR) 0,8 per l’ULN o ≤ 3 per i pazienti che ricevono anticoagulanti, quali coumadin o eparina. I pazienti in terapia anticoagulante possono partecipare a condizione che prima della terapia anticoagulante non sia stato evidenziato nessun difetto di base della coagulazione. 11. Test di gravidanza su siero negativo per le donne in età fertile, eseguito nei 14 giorni precedenti alla randomizzazione (se richiesto dalle normative locali, il test deve essere eseguito nelle 72 ore precedenti alla randomizzazione). Per l'elenco completo si prega di fare riferimento al protocollo di studio.
    E.4Principal exclusion criteria
    1. >1 prior systemic regimen (prior MET inhibitors/antibodies are not allowed; experimental systemic therapy for inoperable HCC given before or after sorafenib counts as separate regimen and is not allowed) 2. Child-Pugh B-C cirrhotic status based on clinical findings and laboratory results during screening period (see Appendix 17.4 for Child-Pugh Classification and interpretation of ascites at physical examination and Prothrombin Time (PT)/ International Normalized Ratio (INR)) 3. Previous or concurrent cancer that is distinct from HCC in primary site or histology, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Ta, Tis & T1). Any cancer curatively treated > 3 years prior to enrollment is permitted. 4. History of congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification (see Appendix 17.5) within 6 months prior to study entry; active coronary artery disease (CAD); clinically significant bradycardia or other uncontrolled, cardiac arrhythmia defined as ≥ Grade 3 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to study entry (myocardial infarction occurring > 6 months prior to study entry is permitted) 5. Active clinically serious infections defined as ≥ Grade 3 according to NCI CTCAE, version 4.03 6. Any medical, psychological, or social conditions, particularly if unstable, including substance abuse, that may, in the opinion of the Investigator, interfere with the subject’s safety or participation in the study, protocol compliance, or evaluation of the study results 7. Known human immunodeficiency virus (HIV) infection 8. Blood or albumin transfusion within 5 days prior to the blood draw being used to confirm eligibility 9. Concomitant interferon therapy or therapies for active Hepatitis C Virus (HCV) infection 10. Pregnancy or breast-feeding 11. History of liver transplant 12. Inability to swallow oral medications 13. Clinically significant gastrointestinal bleeding occurring ≤ 4 weeks prior to randomization
    1. Più di un regime sistemico pregresso (non sono consentiti inibitori di MET/anticorpi anti-MET, la terapia sistemica sperimentale per HCC non operabile somministrata prima o dopo sorafenib è considerata come un regime separato e non è consentita). 2. Cirrosi di classe B-C secondo la classificazione di Child-Pugh in base ai riscontri clinici ed ai risultati di laboratorio (fare riferimento all’Appendice 17.4 per la Classificazione di Child-Pugh e l’interpretazione di asciti all’esame obiettivo e del tempo di protrombina, PT/rapporto internazionale normalizzato, INR). 3. Tumore precedente o concomitante diverso dall’HCC per sede primaria o caratteristiche istologiche, AD ECCEZIONE del carcinoma della cervice in situ, del carcinoma basocellulare trattato e dei tumori superficiali della vescica (Ta, Tis e T1). È consentito qualsiasi tumore curato &gt; 3 anni prima dell’arruolamento. 4. Anamnesi di insufficienza cardiaca congestizia di classe da II a IV secondo la classificazione della New York Heart Association (NYHA) (fare riferimento all’Appendice 17.5) nei 6 mesi precedenti all’entrata nello studio; coronaropatia attiva (CAD); bradicardia clinicamente significativa o altra patologia non controllata; aritmia cardiaca definita di Grado ≥ 3 secondo i criteri comuni di terminologia per gli eventi avversi (CTCAE) del National Cancer Institute (NCI), versione 4.03, o ipertensione non controllata, o infarto miocardico nei 6 mesi precedenti all’entrata nello studio (è consentito l’infarto miocardico verificatosi &gt; 6 mesi precedenti all’inizio dello studio). 5. Infezioni attive clinicamente gravi definite di Grado ≥ 3 secondo l’NCI-CTCAE, versione 4.03. 6. Qualsiasi condizione medica, psicologica o sociale, soprattutto se instabile, che comprende l’abuso di sostanze, che secondo lo Sperimentatore potrebbe interferire con la sicurezza del paziente, con la sua partecipazione allo studio, con la compliance al protocollo o con la valutazione dei risultati dello studio. 7. Infezione nota da virus dell’immunodeficienza umana (HIV) 8. Trasfusione di sangue o di albumina nei 5 giorni precedenti al prelievo di sangue per la conferma dell’eleggibilità per lo studio. 9. Terapia concomitante con interferone o terapie per l’infezione attiva da virus dell’epatite C (HCV). 10. Gravidanza o allattamento. 11. Anamnesi di trapianto di fegato. 12. Incapacità di deglutire medicinali orali. 13. Emorragia gastrointestinale clinicamente significativa ≤ 4 settimane precedenti la randomizzazione.
    E.5 End points
    E.5.1Primary end point(s)
    Overall survival (OS) in the intent-to-treat (ITT) population
    Sopravvivenza globale (OS) nella popolazione intent-to-treat (ITT).
    E.5.1.1Timepoint(s) of evaluation of this end point
    38 months
    38 mesi
    E.5.2Secondary end point(s)
    Progression free survival (PFS) by central, independent radiology review
    Sopravvivenza libera da progressione (PFS) mediante revisione radiologica centrale, indipendente.
    E.5.2.1Timepoint(s) of evaluation of this end point
    38 months
    38 mesi
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned19
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA112
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Brazil
    Canada
    Mexico
    New Zealand
    Switzerland
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Please refer to the protocol
    Si prega di fare riferimento al protocollo clinico
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months38
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months38
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 0
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 263
    F.4.2.2In the whole clinical trial 303
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Please refer to the protocol
    Si prega di fare riferimento al protocollo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-12-20
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-11-13
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA